AMBEV S.A. - SPONSORED ADR (ABEV)

CUSIP: 02319V103

Q4 2017 13F Holders as of 31 Dec 2017

Share change
-16,048,688
Put/Call ratio
0%
SEC-reported price per share
$6.46
Indexed holders
318
Value change
-$104,222,818
Number of buys
151
Open additional details 1 more signal available
Number of sells
120

Security key

02319V103

Report period

Q4 2017

Indexed institutions

318

Top holders

10

Ownership snapshot

Top reported holders of ABEV - AMBEV S.A. - SPONSORED ADR (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
VONTOBEL ASSET MANAGEMENT...
Disclosed value leader
VONTOBEL ASSET MANAGEMENT...
Comparable rows
0/15
Latest evidence
30 Sep 2017
13F Highest disclosed value: $1,133,290,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

VONTOBEL ASSET MANAGEMENT INC has the largest disclosed position value at $1.13B.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens VONTOBEL ASSET MANAGEMENT INC's linked filing trail.
Disclosed position value Top 5
VONTOBEL ASSET MANAGEMENT INC $1.13B
LAZARD ASSET MANAGEMENT LLC $643.4M
JPMORGAN CHASE & CO $592.22M
MASSACHUSETTS FINANCIAL SERVICES ... $523.08M
MANNING & NAPIER ADVISORS LLC $347.04M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
VONTOBEL ASSET MANAGEMENT INC
13F
Company
13F
—
denominator unverified
$1,133,290,000
169,612,387 shares
— 30 Sep 2017
LAZARD ASSET MANAGEMENT LLC
13F
Company
13F
—
denominator unverified
$643,400,000
97,633,046 shares
— 30 Sep 2017
JPMORGAN CHASE & CO
13F
Company
13F
—
denominator unverified
$592,218,000
90,277,034 shares
— 30 Sep 2017
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
13F
Company
13F
—
denominator unverified
$523,078,000
79,374,508 shares
— 30 Sep 2017
MANNING & NAPIER ADVISORS LLC
13F
Company
13F
—
denominator unverified
$347,045,000
52,662,595 shares
— 30 Sep 2017
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$253,403,000
38,452,606 shares
— 30 Sep 2017
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2017

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
318
Shares
1,138,242,946
Indexed holders
318
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q4 2017 vs Q3 2017 Across Filers

Q3 2017 indexed holders
306
Q4 2017 indexed holders
318
Indexed holder difference
12
Investor Q3 2017 Shares Q4 2017 Shares Share Diff Share Chg % Q3 2017 value Q4 2017 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .